These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8583224)

  • 1. Interleukin-2 Pseudomonas exotoxin chimeric protein is cytotoxic to B cell cultures derived from myasthenia gravis patients.
    Steinberger I; Brenner T; Lorberboum-Galski H
    J Neurol Sci; 1995 Nov; 133(1-2):183-91. PubMed ID: 8583224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2 pseudomonas exotoxin (IL2-PE66(4)Glu) chimeric protein kills B cells from patients with Myasthenia gravis.
    Steinberger I; Brenner T; Lorberboum-Galski H
    Cell Immunol; 1996 Apr; 169(1):55-61. PubMed ID: 8612294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes.
    Lorberboum-Galski H; Garsia RJ; Gately M; Brown PS; Clark RE; Waldmann TA; Chaudhary VK; FitzGerald DJ; Pastan I
    J Biol Chem; 1990 Sep; 265(27):16311-7. PubMed ID: 1975810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors.
    Ogata M; Lorberboum-Galski H; FitzGerald D; Pastan I
    J Immunol; 1988 Dec; 141(12):4224-8. PubMed ID: 3264309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 (IL-2) receptor alpha, beta and gamma subunit expression as a function of B-cell lineage ontogeny: the use of IL-2-PE66(4Glu) to characterize internalization via IL-2 receptor subunits.
    Steinberger I; Ben-Bassat H; Hochberg E; Lorberboum-Galski H
    Scand J Immunol; 1997 Aug; 46(2):129-36. PubMed ID: 9583993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein.
    Joshi BH; Leland P; Puri RK
    Croat Med J; 2003 Aug; 44(4):455-62. PubMed ID: 12950150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
    Kioi M; Kawakami K; Puri RK
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma.
    Kreitman RJ; Siegall CB; FitzGerald DJ; Epstein J; Barlogie B; Pastan I
    Blood; 1992 Apr; 79(7):1775-80. PubMed ID: 1558971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
    Yao X; Zhao J; Kong Q; Xie X; Wang J; Sun B; Xu L; Mu L; Li H
    Immunol Invest; 2018 Oct; 47(7):712-724. PubMed ID: 29944018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.
    Lorberboum-Galski H; FitzGerald D; Chaudhary V; Adhya S; Pastan I
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1922-6. PubMed ID: 3126499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.
    Siegall CB; Kreitman RJ; FitzGerald DJ; Pastan I
    Cancer Res; 1991 Jun; 51(11):2831-6. PubMed ID: 1851660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.
    Husain SR; Gill P; Kreitman RJ; Pastan I; Puri RK
    Mol Med; 1997 May; 3(5):327-38. PubMed ID: 9205948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.
    Vrolix K; Fraussen J; Losen M; Stevens J; Lazaridis K; Molenaar PC; Somers V; Bracho MA; Le Panse R; Stinissen P; Berrih-Aknin S; Maessen JG; Van Garsse L; Buurman WA; Tzartos SJ; De Baets MH; Martinez-Martinez P
    J Autoimmun; 2014 Aug; 52():101-12. PubMed ID: 24439114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning and expression of the gene coding for IL-2(60)-PE40, a molecular targeted protein.
    Zhang M; Zhao X; Li H; Lu S
    Chin Med Sci J; 1995 Sep; 10(3):136-40. PubMed ID: 8580481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
    Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
    Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of T cell subpopulations and recombinant interleukin (IL)-2 on peripheral B cell function in patients with myasthenia gravis.
    Zhang J; Zhou WB; Wang HL; Guo SS
    Hum Antibodies; 1997; 8(2):90-4. PubMed ID: 9289393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cells produce less IL-10, IL-6 and TNF-α in myasthenia gravis.
    Yilmaz V; Oflazer P; Aysal F; Parman YG; Direskeneli H; Deymeer F; Saruhan-Direskeneli G
    Autoimmunity; 2015 Jun; 48(4):201-7. PubMed ID: 25518708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of internalization-deficient cells by interleukin-2-Pseudomonas exotoxin chimeric protein: the cytoplasmic domain of the interleukin-2 receptor beta chain does not contribute to internalization of interleukin-2.
    Furse RK; Malek TR
    Eur J Immunol; 1993 Dec; 23(12):3181-8. PubMed ID: 8258333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG; Duan RS; Zhu WH; Lu CZ
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.